Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move
(TSXV: $KHRN.V) (CSE: $ABCS.C) (TSX: $FIRE.TO) (CSE: $CURA.C) (TSXV: $HVT.V)
(CSE: $NTAR.C)
Delta, Kelowna, BC –July
17, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07171KHRN-ABCS-FIRE-CURA-HVT-NTAR.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
In today’s podcast we look at a few early
announcements.
Khiron Life Sciences Corp. (TSXV:
KHRN) (OTCQB:
KHRNF) announced
today that it has received approval from the
National Cultivar Registry and the Technical Direction of the ICA for the
commercialization of 17 stains of cannabis. The approvals bring the total
number of registered strains to 22 and positions the Company to commercialize and
distribute CBD cannabis, which is currently being cultivated at Khiron's
facility near Ibague, Colombia. This development, which results from a
successful ICA operational review, firmly positions the Company to
commercialize its medical cannabis product sales in the third quarter of
2019.
The Company intends to begin commercial
production of CBD extract in 2019. This production will be used primarily to
produce medicine and sold to patients individually as specifically prepared
formulations. This direct to patient distribution method is anticipated to
deliver higher margins than producers focused on wholesale export distribution
models. Based on independent market research, it is estimated that Colombia has
upwards of 6 million potential patients for medical cannabis products (IMS
Quintiles). Benefitting from the proprietary independent market research Khiron
has commissioned, the Company's medical and scientific teams will utilize
state-of-the-art cultivation and extraction processes to produce a portfolio of
predefined, precise, and effective formulations to address the unmet medical
needs of patients.
In addition to commercializing CBD
production, the Company's proprietary psychoactive cannabis varieties
("THC") have now undergone and completed a rigorous regulatory
process to receive strain approval from ICA. With these strain approvals,
Khiron can now work to obtain approval of the THC strains for commercial quota
issuance with the Quota Technical Group. Before commercial quotas can be
awarded, the Company must demonstrate an established market demand and
distribution method. Based on the potential addressable patient network Khiron
has established with medical associations and the ILANS acquisition, the
Company believes it has established a leading position in terms of receiving a
favorable quota allocation. To date there have been no awards of commercial
quotas for THC in Colombia.
Alvaro Torres, CEO of Khiron Life
Sciences, commented, "Khiron has continually focused on expediting our
timing to market, while ensuring the highest standards of product quality and
consistency. With these approvals secured, Khiron is now poised to introduce
its medical cannabis products in Colombia by the third quarter of this year,
which once again, demonstrates the Company's in-depth understanding of patient
needs, its strategic and evidence-based approach, unparalleled regulatory
knowledge, and its leadership role in the Latin American market."
Abacus Health Products, Inc. (CSE:
ABCS) (OTCQX:
ABAHF) today
announced a new retail purchase order by Valu
Merchandisers Company for its line of CBDMEDIC™ products.
Valu Merchandisers is a cooperative food
distributor serving over 3,800 independently-owned supermarkets in 30 U.S.
states and who confirmed an order with Abacus that will see 11 SKUs from the
CBDMEDIC™ product line placed in 350 retail stores across six states, with
expansion to more than 1,000 locations over the next six months. This new
purchase order increases Abacus' total retailer store count to approximately
2,550 locations in 15 states throughout the U.S. The Company remains on track
to reach 4,000 retail locations by the end of Q3 2019, as per the guidance
previously provided by management.
"Valu Merchandisers is a trusted
name in the health and wellness segment and we are delighted that they have
chosen to introduce CBDMEDIC™ to their network," said Perry Antelman, CEO
of Abacus. "This purchase order
further illustrates how we continue to execute on our retail growth strategy
and add retail chains with significant presence across the United States."
The Supreme Cannabis Company, Inc. (TSX:
FIRE) (OTCQX:
SPRWF)
today announced that it has entered into a definitive
agreement under which Supreme Cannabis will acquire all of the issued and
outstanding shares of privately-held Truverra Inc., to be effected by way of a
three-cornered amalgamation between Truverra, Supreme Cannabis and a
wholly-owned subsidiary of Supreme Cannabis. The Transaction is valued at 14.7
million common shares of Supreme Cannabis, giving the Transaction an
approximate dollar value of $20,000,000 as of the Company's closing price on
July 16, 2019.
Located in Toronto, Truverra is a private
cannabis company, serving the Canadian and international cannabis markets
through its wholly-owned subsidiaries, Canadian Clinical Cannabinoids Inc. and Truverra (Europe) B.V.
CCC operates a 5,000 square-foot Health
Canada licensed facility in Scarborough, Ontario. Supreme Cannabis intends to
repurpose CCC's state-of-the-art facility to produce high-quality cannabis
extracts, including concentrates and vaping liquids. In addition to its
operations in Canada, Truverra's wholly-owned European subsidiary, Truverra
Europe, is located in the Netherlands and sells a broad portfolio of hemp-based
CBD products into select European markets.
"The recent introduction of Health
Canada's amended cannabis regulations creates a distinct opportunity for
Supreme Cannabis to establish a leading position in the cannabis extracts
markets. With the acquisition of Truverra, we secure a Toronto-based facility
equipped to extract our high-quality inputs for concentrates and vaping liquids
in the near-term," said Navdeep Dhaliwal, CEO of Supreme Cannabis.
"Truverra's operations also provide an additional entry point into
Europe's CBD wellness market, where Truverra Europe has successfully launched
multiple CBD products in various jurisdictions. Truverra's Canadian and
European operations are managed by a senior leadership team with a wealth of
experience manufacturing and launching products in highly-regulated industries
such as life sciences and pharmaceuticals."
"The Supreme Cannabis Company has a
strong track record for executional excellence, with their support and robust
corporate services we look forward to strengthening our operations in Canada
and globally," said Jeff Adams, CEO of Truverra. "In the near term,
we will continue to build Truverra's CBD offering in Europe and position the
brand to serve international medical markets."
Curaleaf Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF)
today announced that it has signed a definitive
agreement to acquire GR Companies, Inc. ("Grassroots"), the largest
private vertically-integrated multi-state operator, in a cash and stock deal
valued at approximately $875 million. This transaction solidifies Curaleaf's position
as the world's largest cannabis company by revenue and the largest in the U.S.
across key operating metrics.
The highly complementary acquisition
brings together the largest public and largest private multi-state operators in
the U.S. to offer a full range of products to consumers in states across the
country. As a market leader throughout the Midwest, Grassroots has a portfolio
of 61 dispensary licenses, with 20 operating today, and 17 cultivation and
processing licenses that will substantially accelerate Curaleaf's continued
expansion across the nation.
Grassroots has a leading presence in
large markets in which Curaleaf presently does not operate, including Illinois,
which in June became the 11th state to legalize adult-use cannabis, and Pennsylvania,
the fifth most populous state in the U.S. The proposed transaction will expand
Curaleaf's presence from 12 to 19 states, and the combined company will have
131 dispensary licenses, 68 operational locations, 20 cultivation sites and 26
processing facilities1. With the acquisition, Curaleaf will also add
new markets in Arkansas, Michigan, North Dakota, Oklahoma, and Vermont, and
build on its existing businesses in Connecticut, Maryland, Nevada and Ohio.
Upon completion of the proposed transaction, Curaleaf will be the largest
medical and adult-use cannabis company with access to a total population of
approximately 177 million people.
"With the acquisition of Grassroots
and the pending acquisition of Select, Curaleaf is the world's largest cannabis
company by both revenue and operating presence," said Joseph Lusardi, CEO
of Curaleaf. "With a combined 68 open dispensaries, this transaction
significantly accelerates our expansion strategy and strengthens our reach
across the medical and adult-use markets. In addition, it enhances the depth of
our retail and wholesale platform across the country. By leveraging our scale,
as well as our market leading capabilities and expertise, we will continue to
deliver value for our shareholders."
Mitch Kahn, co-founder and CEO of
Grassroots, said, "Today's announcement is a testament to the hard work of
the many employees that helped make Grassroots the leading cannabis company in
the Midwest. This acquisition will enable us to give our patients and retail
partners greater access to products that adhere to the highest standards of
quality and reliability, and our employees the opportunity to be part of a
best-in-class operator."
Harvest One Cannabis Inc. (TSXV:
HVT) (OTCQX:
HRVOF)
today announced that the Company, through its
wholly-owned subsidiary, Satipharm Ltd., has entered into a Supply Agreement
with GenCanna Global USA dated June 4, 2019. Under the terms of the Agreement,
GenCanna will supply Harvest One with GMP Certified CBD oil and finished
products for distribution in regulated markets in the United States, Europe,
and around the globe, currently under the Dream Water, Satipharm, and
LivRelief™ brands for an initial term of two years. In addition, GenCanna will
support the Company in the research, development, and formulation of both
existing and new CBD-infused products.
With
an industry-leading 38,000+ retail distribution points around the globe
(including, Walmart US, CVS, Kroger, Shoppers Drug Mart, Loblaw, Holland &
Barrett and Boots), Harvest One is quickly becoming a leading global house of
brands in the health, wellness, and self-care sectors, with cannabis,
cannabis-infused, and all-natural product offerings. From Satipharm's patented
GelPell® CBD capsules, to Dream Water's all natural, single shot sleep
products, and the recent addition of LivRelief™, Canada's leading all natural
topical pain relief cream, the Agreement with GenCanna ensures the consistent
supply of premium quality hemp-derived CBD for infusion of our existing
products and further product innovation.
"Working with world-class partners
like GenCanna to supply premium quality, traceable, consistent ingredients, all
from GMP-certified facilities, is critical to our core strategy at Harvest One
to only offer consumers best-in-class premium products, with consistent and
predictable effects, in delivery formats they have come to understand and
demand" said Grant Froese, Chief Executive Officer of Harvest One. Mr.
Froese added, "this Agreement signals the beginning of a global
relationship with GenCanna under which we will continue to innovate, infuse our
existing portfolio of products, and bring new products to market under our
well-recognized and trusted, Satipharm, Dream Water, and LivRelief™
brands".
"Our
evolving relationship with Harvest One reflects both companies' devotion to
consumer product quality" said Steve Bevan, Executive Chair of GenCanna.
"Joint research and development have combined to provide excellent CBD
product additions to Harvest One's suite of leading-edge brands. We expect that
consumers will quickly welcome these products on retail shelves globally"
added Steve Bevan.
NexTech AR Solutions (OTCQB:
NEXCF) (CSE:
NTAR)
announced that it has entered into an agreement
with Touchstone Home Products to
ARitize™ its product line. NexTech AR and Touchstone Home Products, Inc. are
launching a 6 product step-off into web-based AR experiences for e-retail, with
future plans to fully ARitize the Touchstone Home Products, Inc. line of home
furnishings, harnessing the power of conversion-boosting webAR experiences.
Frank Quinlisk, Touchstone Home Products
Vice President of Marketing, explains, “Furniture shopping is a very tangible
process. With NexTech AR technology, we are able to bring our TV Lift Cabinet
and Fireplace showroom experiences to life. Online shoppers can view the TV
lift cabinet or Electric Fireplaces from every angle and zoom in to see the
quality construction up close. We are pleased to offer this in-depth product
view to our customers who aren’t able to visit our showroom in person.”
NexTech’s ARitize™ eCommerce solution is
a monthly software as a service (SaaS) software licensing and delivery model in
which software is licensed on a subscription basis while being centrally hosted
in the cloud. NexTech’s SaaS subscription platform enables companies like
Touchstone to transform 2D images into true 3D AR experiences. Utilizing simple
embed coding, NexTech’s browser-based technology eliminates the gap online
shoppers feel between themselves and the product, allowing them to effectively
try or place the product in their home before they buy it.
“I am pleased that we are continuing to
execute on our business plan of signing up customers to our SaaS subscription
platform for our webAR e-commerce solutions, as every customer we sign up
brings us one step closer to profitability,” comments Evan Gappelberg, CEO of
NexTech. “Our webAR product images and rotation capabilities are the best on
the market and will enable buyers to fully examine and understand the product
before they buy, similar to how they would experience in-store shopping. We’re
excited to help Touchstone provide its customers with a one-of-a-kind immersive
eCommerce experience.”
Gartner
recently reported that roughly 100 million consumers will
shop in augmented reality online and in-store by 2020.
“Retailers are under increasing pressure
to explain the purpose of physical stores, and take control of the fulfillment
and return process for cross-channel execution,” said Hanna Karki, principal research analyst at Gartner.
“At the same time, consumers are progressively defining the value provided by
the experiences they receive from retailers. As a result of these pressures,
retailers are turning to AR and VR to offer customers a unified retail
experience inside and outside retail stores.”
NexTech is building out its AR and AI
eCommerce offerings, which include using AI to create a guided and
knowledgeable curator that can be programmed to be used for eCommerce or for
education in the medical device market.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
